Adjacent Evidence Brief: Longevity vitamin — full paper

Researka accepted publication: 49fee64b-298a-43fc-b595-36c94c769e98 Source submission: f1146a1b-ec32-4de9-9028-5e7391723d4d This paper synthesizes evidence on Longevity vitamin across 22 accepted source papers and 559 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 18 adjacent clinical sources, and 4 mechanistic or model-system sources, with 15 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the cardiometabolic, mechanism and contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, immune and inflammation, deficiency prevalence outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Longevity vitamin remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.